Half-year report · Q2
4539.TEDINET S100UPF3
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥30.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥76m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥298m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥219m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥62m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥27m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥180m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥44m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥31m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥52.0bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥49.5bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥50.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥33.5bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥31.1bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.6bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥18.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.8bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥702m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥296m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥592m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥88m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-12.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-50.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.72 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.5% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥627m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥570m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥61m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥61m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.1bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥15.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥546m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥56m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥5m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥5m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.3bn |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00957-000Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥355m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | −¥298m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 534
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 56000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | -298000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | -298000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 15055000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 570000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 15626000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 15626000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 4000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 56000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 61000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -61000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 15059000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 627000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 15687000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -61000000 | JPY |
| Net sales | CurrentYTDDuration | 15626000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00957-000MedicineReportableSegmentsMember | 38000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 38000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 76000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 76000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第93期中(自 2024年４月１日 至 2024年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)日本ケミファ株式会社 | |
| Company name in english cover page | FilingDateInstant | NIPPON CHEMIPHAR CO., LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山 口 一 城 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京(03)3863－1211大代表 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員管理部長 中 島 慎 司 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区岩本町二丁目２番３号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京(03)3863－1211大代表 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員管理部長 中 島 慎 司 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00957 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45390 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)日本ケミファ株式会社 | |
| Filer name in english | FilingDateInstant | NIPPON CHEMIPHAR CO., LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |